Literature DB >> 9919323

Conventional vs. newer antipsychotics in elderly patients.

D V Jeste1, E Rockwell, M J Harris, J B Lohr, J Lacro.   

Abstract

Elderly patients with schizophrenia and dementia patients with agitation are frequently candidates for antipsychotic treatment. Conventional neuroleptics have relatively little effect on negative symptoms and may cause considerable side effects, especially in elderly patients. The authors have found a 29% cumulative annual incidence of tardive dyskinesia (TD) in middle-aged and elderly outpatients treated with relatively low doses of conventional neuroleptics Newer antipsychotics are less likely to cause extrapyramidal symptoms and may be associated with a lower risk of TD. They are generally effective for both positive and negative symptoms and may also improve some aspects of cognition, but these drugs have their own side effects. Dosing requirements for elderly patients tend to be much lower than those for younger adults.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9919323

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  34 in total

1.  Drug review "surprises" reader.

Authors:  R W Shulman
Journal:  Can Fam Physician       Date:  2000-12       Impact factor: 3.275

Review 2.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Antipsychotic treatment for late-life schizophrenia.

Authors:  Jeremy A Sable; Dilip V Jeste
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

4.  Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland.

Authors:  Helka Hosia-Randell; Kaisu Pitkälä
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Can medication-free research ever be ethical in older people with psychotic disorders?

Authors:  Dilip V Jeste
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

Review 7.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

8.  Treatment changes among older patients with dementia treated with antipsychotics.

Authors:  Hyungjin Myra Kim; Claire Chiang; Daniel Weintraub; Lon S Schneider; Helen Kales
Journal:  Int J Geriatr Psychiatry       Date:  2015-03-11       Impact factor: 3.485

9.  Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.

Authors:  Yakup Albayrak; Kenji Hashimoto
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-08

Review 10.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.